Evidence of Chikungunya virus seroprevalence in Myanmar among dengue-suspected patients and healthy volunteers in 2013, 2015, and 2018

• Material Type: 博士論文
• Title: Evidence of Chikungunya virus seroprevalence in Myanmar among dengue-suspected patients and healthy volunteers in 2013, 2015, and 2018
• Author/Editor: Luvai, Elizabeth Ajema Chebichi
• Author Heading: Luvai, Elizabeth Ajema Chebichi
• Publication, Distribution, etc.: PLOS
• Publication Date: 2022-03-18
• Publication Date (W3CDTF): 2022-03-18
• Alternative Title: 2013年、2015年、2018年のミャンマー国におけるデング熱疑い患者および、一般健康人のチクングニヤウイルスに対する血清疫学調査
• Periodical title: PLoS Neglected Tropical Diseases
• No. or year of volume/issue: 15 12
• Volume: 15
• Issue: 12
• Pages: e0009961-
• ISSN (Periodical Title): ISSN : 1935-2735
• Degree grantor/type: Nagasaki University (長崎大学)
• Date Granted: 2022-03-18
• Dissertation Number: 甲医歯薬第1439号
• Degree Type: 博士(医学)
• Text Language Code: eng
• Target Audience: 一般
• Note (General): Introduction: Chikungunya virus (CHIKV) is a mosquito-borne virus known to cause acute febrile illness associated with debilitating polyarthritis. In 2019, several institutions in Myanmar reported a CHIKV outbreak. There are no official reports of CHIKV cases between 2011 and 2018. Therefore, this study sought to determine the seroprevalence of CHIKV infection before the 2019 outbreak.Methods: A total of 1,544 serum samples were collected from healthy volunteers and patients with febrile illnesses in Yangon, Mandalay, and the Myeik district in 2013, 2015, and 2018. Participants ranged from one month to 65 years of age. Antibody screening was performed with in-house anti-CHIKV IgG and IgM ELISA. A neutralization assay was used as a confirmatory test.Results: The seroprevalence of anti-CHIKV IgM and anti-CHIKV IgG was 8.9% and 28.6%, respectively, with an overall seropositivity rate of 34.5%. A focus reduction neutralization assay confirmed 32.5% seroprevalence of CHIKV in the study population. Age, health status, and region were significantly associated with neutralizing antibodies (NAbs) and CHIKV seropositivity (p < 0.05), while gender was not (p = 0.9). Seroprevalence in 2013, 2015, and 2018 was 32.1%, 28.8%, and 37.3%, respectively. Of the clinical symptoms observed in participants with fevers, arthralgia was mainly noted in CHIKV-seropositive patients.Conclusion: The findings in this study reveal the circulation of CHIKV in Myanmar’s Mandalay, Yangon, and Myeik regions before the 2019 CHIKV outbreak. As no treatment or vaccine for CHIKV exists, the virus must be monitored through systematic surveillance in Myanmar.; 長崎大学学位論文 学位記番号:博(医歯薬)甲第1439号 学位授与年月日:令和4年3月18日; Author: Elizabeth Ajema Chebichi Luvai, Aung Kyaw Kyaw, Nundu Sabiti Sabin, Fuxun Yu, Saw Wut Hmone, Kyaw Zin Thant, Shingo Inoue, Kouichi Morita, Mya Myat Ngwe Tun; Citation: PLoS Neglected Tropical Diseases, 15(12), art.no. e0009961; 2021; identifier:Nagasaki University (長崎大学), 博士(医学) (2022-03-18)
• Source: fulltext; https://nagasaki-u.repo.nii.ac.jp/?action=repository_action_common_download&item_id=27421&item_no=1&attribute_id=70&file_no=1
• Access Restrictions: インターネット公開
• Rights (production): © 2021 Luvai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
• Related Material: http://hdl.handle.net/10069/00041442
• Related Material (DOI): 10.1371/journal.pntd.0009961
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 長崎大学 : 長崎大学学術研究成果リポジトリ